Business
Currency:EUR
2023/FY
Stock NameRevenueRatio
Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to18.87M36.36%
Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to15.8M30.44%
Monalizumab agreement - AstraZeneca9.5M18.30%
Takeda agreement 20234.55M8.77%
Sanofi agreement 20162M3.85%
Invoicing of research and development costs (IPH5201)1.17M2.24%
Others11K0.02%
View all
Region
Currency:EUR
2023/FY
Stock NameRevenueRatio
France51.9M100.00%
